Navigation Links
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Date:9/23/2009

RICHMOND, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic(TM) approach, however subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.

"Opening a second Phase 1 clinical trial of this exciting new approach to HIV/AIDS treatment enables us to expedite clinical and commercial development of SB-728-T. We are very pleased with the FDA's decision enabling us to expand this program and move forward quickly with a repeat-dosing trial," said Dale Ando, M.D., Sangamo's chief medical officer and vice president of therapeutic development.

"The best approach to controlling HIV is by preventing infection of cells in the first place. Since 1996, when CCR5 was validated as a target for HIV therapy, the goal has been to recapitulate the naturally-occurring protection against viral infection exhibited by individuals who have the CCR5-delta32 mutation. We have the ability to disrupt the CCR5 gene and make human T-cells resistant to infection by CCR5-specific strains of HIV. In this trial we will be evaluating SB-728-T in subjects that have well-controlled levels of virus but have sub-optimal recovery of CD-4+ T-cell counts despite long-term triple drug therapy. This group represents approximately thirty per
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
2. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
3. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
7. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
8. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
9. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
10. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Research and Markets ( ... "The Corporate Reputation of Pharma - The ... report to their offering. The ... now in its fourth edition. This report contains ... For each annual Corporate Reputation report, the author ...
(Date:4/17/2015)... April 17, 2015 Sigma-Aldrich Corporation ... Science and High Technology company, today announced the ... headquarters and state-of-the-art Cell Culture Technical Center ... facility will provide customized support to meet customer ... "Our new Technical Center will significantly ...
(Date:4/17/2015)... TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) today ... USA , has obtained state sales licenses from ... been in close contact with the major nationwide retail ... own label specialty generic products sold through these nationwide ... According to IMS Health, the U.S. pharma ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5
... HealthCare Inc. (OTC Pink: MHCC) announced the appointment of ... Millennium President Chris Amandola commented, "Ed brings deep experience ... have him join our advisory board.  Our Company,s advantage ... and resourceful individuals and he will be a tremendous ...
... ABT ) today announced that the U.S. Food ... Self-Expanding Stent System for the treatment of iliac artery ... affects the lower extremities. Over time, iliac artery disease ... experience chronic pain and suffer permanent disability. This approval ...
Cached Medicine Technology:Millennium HealthCare Appoints Ed Joyce to Company Advisory Board 2Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease 2Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease 3Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease 4
(Date:4/18/2015)... 2015 Review of Ophthalmology magazine and ... for Success’ program for cataract surgeons attending the American ... Diego, where eye surgeon Jeffrey L. Martin, MD will ... Dr. Martin is the Managing Partner of North Shore ... Dr. Martin to lead this year’s discussion on the ...
(Date:4/18/2015)... April 18, 2015 Lowcostcarinsuranceprice.com has released ... rates have on auto insurance prices . ... rates of vehicle theft may have to pay more ... liability auto insurance policies can also offer protection against ... now be compared online on a single website: ...
(Date:4/18/2015)... NC (PRWEB) April 18, 2015 Patients ... risk of developing mesothelioma later in life, but the ... from mesothelioma that is unrelated to radiation. Surviving Mesothelioma ... on its website. Click here to read it ... Australia compared the cases of 45 patients who had ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been undergoing ... to run maintenance on our shipping facilities to update ... PR Director. "It disrupted our regular shipping schedule but ... on track after having completed the maintenance." , Now, ... which has not allowed some calls to come in ...
(Date:4/18/2015)... New York, NY (PRWEB) April 18, 2015 ... their Internal Security Threat Report , which they say, “exposes ... on how many new malware variants were introduced in 2014 ... it took for Zero Day threats to be identified and ... – it is abundantly clear that doing business in a ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... impairment appears to be more common in people with ... a report in the October issue of Archives ... journals. , Approximately 14.6 million Americans had diagnosed ... undiagnosed diabetes, according to background information in the article. ...
... deprived of body,s sleep-wake system ,can,t remember anything, study ... body clock may do more than help guide your ... vital role in learning and memory, say Stanford University ... a functioning circadian system is critical to the rodents, ...
... Earnings Conference Call on October 30 - - Presentation at Oppenheimer,s 19th Annual Healthcare ... ... ... 7 -, SAN DIEGO, Oct. 13 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today ...
... Oshkosh is one of six sites included in national ... because of low cardiac arrest survival rates, OSHKOSH, ... ) announced today that it has,received an additional $1.5 ... to continue a study testing two devices used in ...
... Content Rights Management System, Supports Global Pharma ... Spend, WEST CHESTER, Pa., Oct. 13 ... manufacturer has integrated,Modevity,s Imperium technology to become the ... tracking and reporting,analytics for their new product video ...
... Away, FORT WORTH, Texas, Oct. 13 The ... at the Will Rogers Memorial,Center. The company, which has ... bottles of free Dannon smoothies and demonstrated support,for a ... FitFuture KIDS Fest is to help educate families about ...
Cached Medicine News:Health News:Vision loss more common in people with diabetes 2Health News:Circadian Rhythm Plays Role in Memory 2Health News:Gen-Probe Announces Webcasts of Three Upcoming Investor Events 2Health News:Gen-Probe Announces Webcasts of Three Upcoming Investor Events 3Health News:Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques 2Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:The Dannon Company Sponsors FitFuture KIDS Fest 2Health News:The Dannon Company Sponsors FitFuture KIDS Fest 3
Long handle occluders are approximately 9 inches long....
Basic external reading model....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: